Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Munro, APS; Feng, S; Janani, L; Cornelius, V; Aley, PK; Babbage, G; Baxter, D; Bula, M; Cathie, K; Chatterjee, K; Dodd, K; Enever, Y; Qureshi, E; Goodman, AL; Green, CA; Harndahl, L; Haughney, J; Hicks, A; van der Klaauw, AA; Kanji, N; Libri, V; Llewelyn, MJ; McGregor, AC; Maallah, M; Minassian, AM; Moore, P; Mughal, M; Mujadidi, YF; Holliday, K; Osanlou, O; Osanlou, R; Owens, DR; Pacurar, M; Palfreeman, A; Pan, D; Rampling, T; Regan, K; Saich, S; Bawa, T; Saralaya, D; Sharma, S; Sheridan, R; Thomson, EC; Todd, S; Twelves, C; Read, RC; Charlton, S; Hallis, B; Ramsay, M; Andrews, N; Lambe, T; Nguyen-Van-Tam, JS; Snape, MD; Liu, X; Faust, SN

Journal article

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Abstract:: Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19.

Methods: The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 si...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., … Faust, S. N. (2022). Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, 22(8), 1131–1141.

MLA Style

Munro, A. PS, et al. “Safety, Immunogenicity, and Reactogenicity of BNT162b2 and MRNA-1273 COVID-19 Vaccines given as Fourth-Dose Boosters Following Two Doses of ChAdOx1 NCoV-19 or BNT162b2 and a Third Dose of BNT162b2 (COV-BOOST): a Multicentre, Blinded, Phase 2, Randomised Trial.” Lancet Infectious Diseases, vol. 22, no. 8, Elsevier, 2022, pp. 1131–41.

Chicago Style

Munro, APS, S Feng, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, et al. 2022. “Safety, Immunogenicity, and Reactogenicity of BNT162b2 and MRNA-1273 COVID-19 Vaccines given as Fourth-Dose Boosters Following Two Doses of ChAdOx1 NCoV-19 or BNT162b2 and a Third Dose of BNT162b2 (COV-BOOST): a Multicentre, Blinded, Phase 2, Randomised Trial.” Lancet Infectious Diseases 22 (8): 1131–41.
Share
Print